A citation-based method for searching scientific literature

Sandy Amorim, Anastasios Stathis, Mary Gleeson, Sunil Iyengar, Valeria Magarotto, Xavier Leleu, Franck Morschhauser, Lionel Karlin, Florence Broussais, Keyvan Rezai, Patrice Herait, Carmen Kahatt, François Lokiec, Gilles Salles, Thierry Facon, Antonio Palumbo, David Cunningham, Emanuele Zucca, Catherine Thieblemont. Lancet Haematol 2016
Times Cited: 275







List of co-cited articles
1021 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.
Céline Berthon, Emmanuel Raffoux, Xavier Thomas, Norbert Vey, Carlos Gomez-Roca, Karen Yee, David Christopher Taussig, Keyvan Rezai, Christophe Roumier, Patrice Herait,[...]. Lancet Haematol 2016
283
51

Selective inhibition of BET bromodomains.
Panagis Filippakopoulos, Jun Qi, Sarah Picaud, Yao Shen, William B Smith, Oleg Fedorov, Elizabeth M Morse, Tracey Keates, Tyler T Hickman, Ildiko Felletar,[...]. Nature 2010
46

BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
Jake E Delmore, Ghayas C Issa, Madeleine E Lemieux, Peter B Rahl, Junwei Shi, Hannah M Jacobs, Efstathios Kastritis, Timothy Gilpatrick, Ronald M Paranal, Jun Qi,[...]. Cell 2011
42

Selective inhibition of tumor oncogenes by disruption of super-enhancers.
Jakob Lovén, Heather A Hoke, Charles Y Lin, Ashley Lau, David A Orlando, Christopher R Vakoc, James E Bradner, Tong Ihn Lee, Richard A Young. Cell 2013
30

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
Mark A Dawson, Rab K Prinjha, Antje Dittmann, George Giotopoulos, Marcus Bantscheff, Wai-In Chan, Samuel C Robson, Chun-wa Chung, Carsten Hopf, Mikhail M Savitski,[...]. Nature 2011
23

Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation.
Omer Gilan, Inmaculada Rioja, Kathy Knezevic, Matthew J Bell, Miriam M Yeung, Nicola R Harker, Enid Y N Lam, Chun-Wa Chung, Paul Bamborough, Massimo Petretich,[...]. Science 2020
156
22

Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.
Anastasios Stathis, Emanuele Zucca, Mohamed Bekradda, Carlos Gomez-Roca, Jean-Pierre Delord, Thibault de La Motte Rouge, Emmanuelle Uro-Coste, Filippo de Braud, Giuseppe Pelosi, Christopher A French. Cancer Discov 2016
225
20

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.
Jeremy Lewin, Jean-Charles Soria, Anastasios Stathis, Jean-Pierre Delord, Solange Peters, Ahmad Awada, Philippe G Aftimos, Mohamed Bekradda, Keyvan Rezai, Zhen Zeng,[...]. J Clin Oncol 2018
128
20

Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Emily J Faivre, Keith F McDaniel, Daniel H Albert, Srinivasa R Mantena, Joshua P Plotnik, Denise Wilcox, Lu Zhang, Mai H Bui, George S Sheppard, Le Wang,[...]. Nature 2020
158
19

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
Johannes Zuber, Junwei Shi, Eric Wang, Amy R Rappaport, Harald Herrmann, Edward A Sison, Daniel Magoon, Jun Qi, Katharina Blatt, Mark Wunderlich,[...]. Nature 2011
18

Suppression of inflammation by a synthetic histone mimic.
Edwige Nicodeme, Kate L Jeffrey, Uwe Schaefer, Soren Beinke, Scott Dewell, Chun-Wa Chung, Rohit Chandwani, Ivan Marazzi, Paul Wilson, Hervé Coste,[...]. Nature 2010
17

The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.
Michela Boi, Eugenio Gaudio, Paola Bonetti, Ivo Kwee, Elena Bernasconi, Chiara Tarantelli, Andrea Rinaldi, Monica Testoni, Luciano Cascione, Maurilio Ponzoni,[...]. Clin Cancer Res 2015
179
17

First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors.
Sarina A Piha-Paul, Jasgit C Sachdev, Minal Barve, Patricia LoRusso, Russell Szmulewitz, Sapna Pradyuman Patel, Primo N Lara, Xiaotian Chen, Beibei Hu, Kevin J Freise,[...]. Clin Cancer Res 2019
76
22

Bromodomains: a new target class for drug development.
Andrea G Cochran, Andrew R Conery, Robert J Sims. Nat Rev Drug Discov 2019
192
17

Targeting bromodomains: epigenetic readers of lysine acetylation.
Panagis Filippakopoulos, Stefan Knapp. Nat Rev Drug Discov 2014
837
16

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.
Sarina A Piha-Paul, Christine L Hann, Christopher A French, Sophie Cousin, Irene Braña, Phillippe A Cassier, Victor Moreno, Johann S de Bono, Sara Duckworth Harward, Geraldine Ferron-Brady,[...]. JNCI Cancer Spectr 2019
74
21

Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma.
Bjoern Chapuy, Michael R McKeown, Charles Y Lin, Stefano Monti, Margaretha G M Roemer, Jun Qi, Peter B Rahl, Heather H Sun, Kelly T Yeda, John G Doench,[...]. Cancer Cell 2013
490
15

Targeting MYC dependence in cancer by inhibiting BET bromodomains.
Jennifer A Mertz, Andrew R Conery, Barbara M Bryant, Peter Sandy, Srividya Balasubramanian, Deanna A Mele, Louise Bergeron, Robert J Sims. Proc Natl Acad Sci U S A 2011
810
15

BRD4 and Cancer: going beyond transcriptional regulation.
Benedetta Donati, Eugenia Lorenzini, Alessia Ciarrocchi. Mol Cancer 2018
228
15

RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain.
Sarah Picaud, Christopher Wells, Ildiko Felletar, Deborah Brotherton, Sarah Martin, Pavel Savitsky, Beatriz Diez-Dacal, Martin Philpott, Chas Bountra, Hannah Lingard,[...]. Proc Natl Acad Sci U S A 2013
287
15

BET Proteins as Targets for Anticancer Treatment.
Anastasios Stathis, Francesco Bertoni. Cancer Discov 2018
221
15

First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity.
Sophie Postel-Vinay, Karin Herbschleb, Christophe Massard, Victoria Woodcock, Jean-Charles Soria, Annette O Walter, Flavio Ewerton, Martine Poelman, Neil Benson, Matthias Ocker,[...]. Eur J Cancer 2019
47
29

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Shaokun Shu, Charles Y Lin, Housheng Hansen He, Robert M Witwicki, Doris P Tabassum, Justin M Roberts, Michalina Janiszewska, Sung Jin Huh, Yi Liang, Jeremy Ryan,[...]. Nature 2016
363
13

PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.
Kanak Raina, Jing Lu, Yimin Qian, Martha Altieri, Deborah Gordon, Ann Marie K Rossi, Jing Wang, Xin Chen, Hanqing Dong, Kam Siu,[...]. Proc Natl Acad Sci U S A 2016
415
13

The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription.
Moon Kyoo Jang, Kazuki Mochizuki, Meisheng Zhou, Ho-Sang Jeong, John N Brady, Keiko Ozato. Mol Cell 2005
875
13

Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy.
Ali Alqahtani, Khalil Choucair, Mushtaq Ashraf, Danae M Hammouda, Abduraham Alloghbi, Talal Khan, Neil Senzer, John Nemunaitis. Future Sci OA 2019
151
13

Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies.
Gerald Falchook, Seth Rosen, Patricia LoRusso, Justin Watts, Shilpa Gupta, Catherine C Coombs, Moshe Talpaz, Razelle Kurzrock, Monica Mita, Ryan Cassaday,[...]. Clin Cancer Res 2020
35
37

Histone recognition and large-scale structural analysis of the human bromodomain family.
Panagis Filippakopoulos, Sarah Picaud, Maria Mangos, Tracy Keates, Jean-Philippe Lambert, Dalia Barsyte-Lovejoy, Ildiko Felletar, Rudolf Volkmer, Susanne Müller, Tony Pawson,[...]. Cell 2012
976
12

Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.
Philipp Rathert, Mareike Roth, Tobias Neumann, Felix Muerdter, Jae-Seok Roe, Matthias Muhar, Sumit Deswal, Sabine Cerny-Reiterer, Barbara Peter, Julian Jude,[...]. Nature 2015
334
12


Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition.
Lu Yang, Youyou Zhang, Weiwei Shan, Zhongyi Hu, Jiao Yuan, Jingjiang Pi, Yueying Wang, Lingling Fan, Zhaoqing Tang, Chunsheng Li,[...]. Sci Transl Med 2017
129
11

BET domain co-regulators in obesity, inflammation and cancer.
Anna C Belkina, Gerald V Denis. Nat Rev Cancer 2012
474
11

BET inhibitor resistance emerges from leukaemia stem cells.
Chun Yew Fong, Omer Gilan, Enid Y N Lam, Alan F Rubin, Sarah Ftouni, Dean Tyler, Kym Stanley, Devbarna Sinha, Paul Yeh, Jessica Morison,[...]. Nature 2015
351
11

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.
Jing Lu, Yimin Qian, Martha Altieri, Hanqing Dong, Jing Wang, Kanak Raina, John Hines, James D Winkler, Andrew P Crew, Kevin Coleman,[...]. Chem Biol 2015
560
11

Master transcription factors and mediator establish super-enhancers at key cell identity genes.
Warren A Whyte, David A Orlando, Denes Hnisz, Brian J Abraham, Charles Y Lin, Michael H Kagey, Peter B Rahl, Tong Ihn Lee, Richard A Young. Cell 2013
11

Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials.
Brian K Albrecht, Victor S Gehling, Michael C Hewitt, Rishi G Vaswani, Alexandre Côté, Yves Leblanc, Christopher G Nasveschuk, Steve Bellon, Louise Bergeron, Robert Campbell,[...]. J Med Chem 2016
126
11

Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma.
V Moreno, J M Sepulveda, M Vieito, T Hernández-Guerrero, B Doger, O Saavedra, O Ferrero, R Sarmiento, M Arias, J De Alvaro,[...]. Ann Oncol 2020
22
50

A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma.
Geoffrey I Shapiro, Patricia LoRusso, Afshin Dowlati, Khanh T Do, Caron A Jacobson, Ulka Vaishampayan, Amy Weise, Paolo F Caimi, Joseph Paul Eder, Christopher A French,[...]. Br J Cancer 2021
35
31

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.
Irfan A Asangani, Vijaya L Dommeti, Xiaoju Wang, Rohit Malik, Marcin Cieslik, Rendong Yang, June Escara-Wilke, Kari Wilder-Romans, Sudheer Dhanireddy, Carl Engelke,[...]. Nature 2014
629
10

BET inhibitors: a novel epigenetic approach.
D B Doroshow, J P Eder, P M LoRusso. Ann Oncol 2017
177
10


BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.
Marie-Magdelaine Coudé, Thorsten Braun, Jeannig Berrou, Mélanie Dupont, Sibyl Bertrand, Aline Masse, Emmanuel Raffoux, Raphaël Itzykson, Marc Delord, Maria E Riveiro,[...]. Oncotarget 2015
179
10

Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain.
George S Sheppard, Le Wang, Steven D Fidanze, Lisa A Hasvold, Dachun Liu, John K Pratt, Chang H Park, Kenton Longenecker, Wei Qiu, Maricel Torrent,[...]. J Med Chem 2020
50
20


DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation.
Georg E Winter, Dennis L Buckley, Joshiawa Paulk, Justin M Roberts, Amanda Souza, Sirano Dhe-Paganon, James E Bradner. Science 2015
817
9

Drug Discovery Targeting Bromodomain-Containing Protein 4.
Zhiqing Liu, Pingyuan Wang, Haiying Chen, Eric A Wold, Bing Tian, Allan R Brasier, Jia Zhou. J Med Chem 2017
164
9

Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies.
Mai H Bui, Xiaoyu Lin, Daniel H Albert, Leiming Li, Lloyd T Lam, Emily J Faivre, Scott E Warder, Xiaoli Huang, Denise Wilcox, Cherrie K Donawho,[...]. Cancer Res 2017
74
12


Targeting MYCN in neuroblastoma by BET bromodomain inhibition.
Alexandre Puissant, Stacey M Frumm, Gabriela Alexe, Christopher F Bassil, Jun Qi, Yvan H Chanthery, Erin A Nekritz, Rhamy Zeid, William Clay Gustafson, Patricia Greninger,[...]. Cancer Discov 2013
426
8

Targeting Brd4 for cancer therapy: inhibitors and degraders.
Yingchao Duan, Yuanyuan Guan, Wenping Qin, Xiaoyu Zhai, Bin Yu, Hongmin Liu. Medchemcomm 2018
65
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.